title: Age- and sex-related characteristics of tonic GABA currents in the rat substantia nigra pars reticulata.
abstract: Previous studies have shown that the pharmacologic effects of GABAergic drugs and the postsynaptic phasic GABAAergic inhibitory responses in the anterior part of the rat substantia nigra pars reticulata (SNRA) are age- and sex-specific. Here, we investigate whether there are age- and sex-related differences in the expression of the δ GABAA receptor (GABAAR) subunit and GABAAR mediated tonic currents. We have used δ-specific immunochemistry and whole cell patch clamp to study GABAAR mediated tonic currents in the SNRA of male and female postnatal day (PN) PN5-9, PN11-16, and PN25-32 rats. We observed age-related decline, but no sex-specific changes, in bicuculline (BIM) sensitive GABAAR tonic current density, which correlated with the decline in δ subunit in the SNRA between PN15 and 30. Furthermore, we show that the GABAAR tonic currents can be modified by muscimol (GABAAR agonist; partial GABACR agonist), THIP (4,5,6,7-tetrahydroisoxazolo (5,4-c)pyridin-3-ol: α4β3δ GABAARs agonist and GABACR antagonist), and zolpidem (α1-subunit selective GABAAR agonist) in age- and sex-dependent manner specific for each drug. We propose that the emergence of the GABAAR-sensitive anticonvulsant effects of the rat SNRA during development may depend upon the developmental decline in tonic GABAergic inhibition of the activity of rat SNRA neurons, although other sex-specific factors are also involved.
authors: Saul R. Korey Department of Neurology, Laboratory of Developmental Epilepsy Bronx, Albert Einstein College of Medicine, 1410 Pelham Pkwy South, Kennedy Rm 306, Bronx, NY, 10461, USA, ondrej.chudomel@gmail.com.
authors: O
authors: O
authors: Chudomel
authors: H
authors: H
authors: Hasson
authors: M
authors: M
authors: Bojar
authors: S L
authors: SL
authors: Moshé
authors: A S
authors: AS
authors: Galanopoulou
mesh_terms: D000367:Age Factors; D000818:Animals; D005260:Female; D008297:Male; D009118:Muscimol / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012737:Sex Factors; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism*; D000077334:Zolpidem; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
chemical_list: D011725:Pyridines; D009118:Muscimol; D005680:gamma-Aminobutyric Acid; D000077334:Zolpidem
references: Cell Tissue Res. 2001 Aug;305(2):187-202
references: 11545256
references: Eur J Neurosci. 2006 May;23(9):2423-30
references: 16706849
references: J Neurophysiol. 1992 Jul;68(1):197-212
references: 1381418
references: Epilepsia. 1995 Oct;36(10):960-5
references: 7555959
references: Int J Dev Neurosci. 2003 Aug;21(5):245-54
references: 12850057
references: Nat Neurosci. 2005 Jun;8(6):797-804
references: 15895085
references: Nat Commun. 2011;2:376
references: 21730957
references: Mol Pharmacol. 2000 Dec;58(6):1375-80
references: 11093776
references: Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15230-5
references: 17005728
references: J Physiol. 1993 Dec;472:443-57
references: 7908326
references: Pharmacol Rev. 2005 Dec;57(4):397-409
references: 16382098
references: J Neurosci. 2002 May 15;22(10):RC223
references: 12006605
references: J Neurochem. 2003 Oct;87(2):325-32
references: 14511110
references: J Pharmacol Exp Ther. 2004 Sep;310(3):1234-45
references: 15126642
references: J Neurophysiol. 2002 May;87(5):2624-8
references: 11976398
references: J Neurophysiol. 2005 Aug;94(2):952-60
references: 15772233
references: Mol Pharmacol. 2001 Apr;59(4):814-24
references: 11259626
references: Science. 1989 Sep 22;245(4924):1389-92
references: 2551039
references: Synapse. 1988;2(2):163-73
references: 2844001
references: Ann Neurol. 2001 Nov;50(5):596-601
references: 11706965
references: Mol Membr Biol. 1994 Jan-Mar;11(1):23-30
references: 8019597
references: J Neurosci. 1994 Nov;14(11 Pt 2):7077-86
references: 7525894
references: Exp Neurol. 2003 Oct;183(2):628-37
references: 14552904
references: Epilepsy Curr. 2006 May-Jun;6(3):83-7
references: 16761069
references: Neuropharmacology. 2000 Apr 3;39(6):990-1003
references: 10727709
references: Mol Pharmacol. 1999 Jul;56(1):110-5
references: 10385690
references: Brain Res. 1994 Nov 28;665(1):141-6
references: 7882007
references: Brain Res. 1987 Dec 15;465(1-2):243-50
references: 3440204
references: Brain Res. 1988 Oct 1;471(2):305-8
references: 3179755
references: J Neurophysiol. 2003 Oct;90(4):2690-701
references: 12815026
references: Fed Proc. 1985 May;44(8):2414-24
references: 2985454
references: Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12905-10
references: 10536021
references: J Neurophysiol. 2008 Mar;99(3):1523-34
references: 18216229
references: J Pharmacol Exp Ther. 2006 Mar;316(3):1351-9
references: 16272218
references: Brain Res Dev Brain Res. 1992 Aug 21;68(2):275-7
references: 1327581
references: Br J Pharmacol. 2002 Aug;136(7):965-74
references: 12145096
references: Neuroscience. 2009 Sep 29;163(1):155-67
references: 19531372
references: J Neurosci. 1998 Mar 1;18(5):1693-703
references: 9464994
references: J Physiol. 2008 Feb 15;586(4):965-87
references: 18063661
references: J Neurosci. 2003 Nov 19;23(33):10650-61
references: 14627650
references: Receptors Channels. 1999;6(6):463-75
references: 10635063
references: J Neurosci. 1994 Nov;14(11 Pt 1):6524-31
references: 7965056
references: Brain Res. 1984 Apr;315(2):305-8
references: 6722591
references: Neuroscience. 2000;101(4):815-50
references: 11113332
references: J Neurochem. 1987 Jun;48(6):1677-86
references: 3033146
references: Epilepsy Res. 1998 Sep;32(1-2):213-23
references: 9761322
references: Neurosci Lett. 2006 May 1;398(1-2):1-5
references: 16540244
references: J Physiol. 1996 Dec 15;497 ( Pt 3):753-9
references: 9003560
references: J Neurosci. 1992 Nov;12(11):4151-72
references: 1331359
references: J Physiol. 2003 Apr 1;548(Pt 1):97-110
references: 12588900
references: Brain Res. 1988 Apr 1;467(2):295-7
references: 3378177
references: Nat Rev Neurosci. 2002 Sep;3(9):728-39
references: 12209121
references: J Physiol. 2007 Aug 1;582(Pt 3):1163-78
references: 17525114
references: Science. 1982 Dec 17;218(4578):1237-40
references: 7146907
references: J Neurosci. 2005 Sep 7;25(36):8272-81
references: 16148235
references: Trends Neurosci. 2004 May;27(5):262-9
references: 15111008
references: Mol Pharmacol. 1998 Nov;54(5):928-33
references: 9804628
references: Epilepsy Res. 1998 Apr;30(2):107-14
references: 9600542
references: Science. 2010 Mar 19;327(5972):1515-8
references: 20299596
references: Ital J Neurol Sci. 1998 Aug;19(4):205-10
references: 10933458